High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment.

Saved in:
Bibliographic Details
Main Authors: Baldissera,R.C., Aranha,J.F.P., Oliveira,G.B., Vigorito,A.C., Eid,K.A.B., Miranda,E.C.M., De Souza,C.A.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2002
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000100007
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2002000100007
record_format ojs
spelling oai:scielo:S0100-879X20020001000072001-12-07High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphomaBaldissera,R.C.Aranha,J.F.P.Oliveira,G.B.Vigorito,A.C.Eid,K.A.B.Miranda,E.C.M.De Souza,C.A. Malignant lymphomas High-dose cyclophosphamide Autologous peripheral blood progenitor cell transplantation Salvage therapy Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.35 n.1 20022002-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000100007en10.1590/S0100-879X2002000100007
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Baldissera,R.C.
Aranha,J.F.P.
Oliveira,G.B.
Vigorito,A.C.
Eid,K.A.B.
Miranda,E.C.M.
De Souza,C.A.
spellingShingle Baldissera,R.C.
Aranha,J.F.P.
Oliveira,G.B.
Vigorito,A.C.
Eid,K.A.B.
Miranda,E.C.M.
De Souza,C.A.
High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
author_facet Baldissera,R.C.
Aranha,J.F.P.
Oliveira,G.B.
Vigorito,A.C.
Eid,K.A.B.
Miranda,E.C.M.
De Souza,C.A.
author_sort Baldissera,R.C.
title High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
title_short High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
title_full High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
title_fullStr High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
title_full_unstemmed High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
title_sort high-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
description Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment.
publisher Associação Brasileira de Divulgação Científica
publishDate 2002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000100007
work_keys_str_mv AT baldisserarc highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT aranhajfp highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT oliveiragb highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT vigoritoac highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT eidkab highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT mirandaecm highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
AT desouzaca highdosecyclophosphamidefollowedbyautologousperipheralbloodprogenitorcelltransplantationimprovesthesalvagetreatmentforpersistentorsensitiverelapsedmalignantlymphoma
_version_ 1756391011479715840